MapLight Therapeutics (MPLT) grants RSUs and 31,395 options to CSO

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics Chief Scientific Officer receives new equity awards. On February 5, 2026, Lillie James Woodruff was granted 7,730 restricted stock units of voting common stock and an option to purchase 31,395 shares at an exercise price of $15.7 per share.

The RSUs vest 25% on January 1, 2027, with the remainder vesting in equal quarterly installments, subject to continued service. The stock option vests 25% on February 5, 2027, with the balance vesting in equal monthly installments thereafter. Following the RSU grant, Woodruff beneficially owns 298,862 shares of voting common stock and 31,395 stock options, all held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lillie James Woodruff

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	31,395	$0.00	--
Grant/Award	Voting Common Stock	7,730	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 31,395 shares (Direct); Voting Common Stock — 298,862 shares (Direct)

Footnotes (1)

Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/09/2026 - 05:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lillie James Woodruff

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	02/05/2026		A		7,730⁽¹⁾	A	$0⁽²⁾	298,862	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$15.7	02/05/2026		A		31,395		⁽³⁾	02/04/2036	Voting Common Stock	31,395	$0	31,395	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did MPLT Chief Scientific Officer receive on February 5, 2026?

Lillie James Woodruff received 7,730 restricted stock units and an option for 31,395 shares of voting common stock at an exercise price of $15.7 per share. Both awards vest over time, contingent on continued service with MapLight Therapeutics.

How do the new MPLT restricted stock units for the CSO vest?

The 7,730 RSUs vest 25% on January 1, 2027, with the remaining 75% vesting in equal installments each April 1, July 1, October 1, and January 1 thereafter. Vesting is conditioned on Lillie James Woodruff’s continued service with MapLight Therapeutics.

What is the vesting schedule for the MPLT stock options granted to the CSO?

The option to buy 31,395 shares vests 25% on February 5, 2027, with the remaining 75% vesting in equal monthly installments on the same day of each month. Vesting requires ongoing service with MapLight Therapeutics, Inc.

What does each MPLT RSU granted to the Chief Scientific Officer represent?

Each restricted stock unit represents a contingent right to receive one share of MapLight Therapeutics voting common stock. Shares are delivered only as the RSUs vest over time, assuming Lillie James Woodruff continues to provide service through the applicable vesting dates.

How many MPLT shares does the Chief Scientific Officer beneficially own after these grants?

After the reported transactions, Lillie James Woodruff beneficially owns 298,862 shares of voting common stock directly, plus 31,395 employee stock options. These holdings reflect her equity stake and incentive alignment with MapLight Therapeutics’ long-term performance.

Are the MPLT equity awards to the CSO classified as acquisitions or sales?

Both transactions are coded as acquisitions. The filing reports an acquisition of 7,730 shares of voting common stock through RSUs and an acquisition of 31,395 derivative securities in the form of employee stock options, each granted as part of equity compensation.